Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Sep;30(9):5386-5387.
doi: 10.1245/s10434-023-13513-4. Epub 2023 Apr 21.

ASO Author Reflections: Towards Consensus on Resectability Assessments and Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases

Marinde J G Bond  1 , Cornelis J A Punt  1 , Rutger-Jan Swijnenburg  2   3
Affiliations
Comment

ASO Author Reflections: Towards Consensus on Resectability Assessments and Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases

Marinde J G Bond et al. Ann Surg Oncol. 2023 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

C.J.A.P. has an advisory role for Nordic Pharma. This funding is not related to the current research. M.J.G.B. and R.J.S. declare no potential conflicts of interest.

Comment on

References

    1. Jones RP, Vauthey JN, Adam R, et al. Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg. 2012;99(9):1263–1269. doi: 10.1002/bjs.8835. - DOI - PubMed
    1. Hellingman T, de Swart ME, Joosten JJA, et al. The value of a dedicated multidisciplinary expert panel to assess treatment strategy in patients suffering from colorectal cancer liver metastases. Surg Oncol. 2020;35:412–417. doi: 10.1016/j.suronc.2020.09.024. - DOI - PubMed
    1. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38–47. doi: 10.1016/S1470-2045(09)70330-4. - DOI - PubMed
    1. Huiskens J, Bolhuis K, Engelbrecht MR, et al. Outcomes of resectability assessment of the Dutch Colorectal Cancer Group liver metastases expert panel. J Am Coll Surg. 2019;229(6):523–532. doi: 10.1016/j.jamcollsurg.2019.08.1445. - DOI - PubMed
    1. Ignatavicius P, Oberkofler CE, Chapman WC, et al. Choices of therapeutic strategies for colorectal liver metastases among expert liver surgeons: a throw of the dice? Ann Surg. 2020;272(5):715–722. doi: 10.1097/SLA.0000000000004331. - DOI - PubMed